---
title: ADAR1-regulated cytoplasmic dsRNA-sensing pathway is a novel mechanism of lenalidomide
  resistance in multiple myeloma
date: '2024-12-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39652772/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20241210175340&v=2.18.0.post9+e462414
source: Blood
description: Immunomodulatory agents (IMiDs) are a major class of drugs for treating
  multiple myeloma (MM); however, acquired resistance to IMiDs remains a significant
  clinical challenge. While alterations in cereblon (CRBN) and its pathway are known
  to contribute to IMiD resistance, they account for only 20-30% of cases, and the
  underlying mechanisms in the majority of the resistance cases remain unclear. Here,
  we identified ADAR1 as a novel driver of lenalidomide resistance in MM. We showed
  ...
disable_comments: true
---
Immunomodulatory agents (IMiDs) are a major class of drugs for treating multiple myeloma (MM); however, acquired resistance to IMiDs remains a significant clinical challenge. While alterations in cereblon (CRBN) and its pathway are known to contribute to IMiD resistance, they account for only 20-30% of cases, and the underlying mechanisms in the majority of the resistance cases remain unclear. Here, we identified ADAR1 as a novel driver of lenalidomide resistance in MM. We showed ...